Examining the costs and cost-effectiveness of novel TB regimens
Exploring the cost-effectiveness of the introduction of new TB drugs regimens, including the corresponding costs of drug-susceptability testing to prevent resistance.
LSHTM lead investigator: Anna Vassall
LSHTM staff: Gabriela Gomez
Funding: TB Alliance
Collaborators: Amsterdam Insitute for Global Health and Development
Location: Brazil, Bangladesh, South Africa, Tanzania